MINNEAPOLIS, MN, June 10, 2013 /CNW Telbec/ - BioAmber Inc. ("BioAmber")
(NYSE: BIOA) announced today that the French Autorité des marchés
financiers (AMF) approved BioAmber's prospectus for admission of its
common stock to listing and trading on the Professional Segment of NYSE
Euronext Paris, and has granted visa number 13-265, dated June 10,
2013, on the prospectus. The attention of investors is drawn to the
risk factors described in the prospectus.
BioAmber's common stock will commence trading on the NYSE Euronext Paris
exchange on June 11, 2013 at 09:00 Central European Time under the
symbol "BIOA," and will be denominated in Euros on the Paris exchange.
A Copy of the prospectus can be obtained free of charge from BioAmber
Inc. by writing to the company at 1250 Rene Levesque West, Suite 4110,
Montreal, Quebec, Canada H3B-4W8, or from the company website (www.bio-amber.com), or from its paying agent, BNP Paribas Securities Services (Postal
address: 3, rue d'Antin, 75002, France), or from the AMF website (www.amf-france.org).
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
About BioAmber Inc.
BioAmber is a sustainable chemicals company. Its proprietary technology
platform combines industrial biotechnology and chemical catalysis to
convert renewable feedstock into chemicals for use in a wide variety of
everyday products including plastics, resins, food additives and
personal care products. For more information about BioAmber visit www.bio-amber.com
This press release contains forward-looking statements, which are
subject to substantial risks, uncertainties and assumptions. These
statements often include words such as "believe," "expect,"
"anticipate," "intend," "plan," "estimate," "seek," "will," "may" or
similar expressions. Although we believe that the expectations
reflected in the forward-looking statements are reasonable, we cannot
guarantee that the events and circumstances reflected in the
forward-looking statements will be achieved or occur and the timing of
events and circumstances and actual results could differ materially
from those projected in the forward- looking statements. Accordingly,
you should not place undue reliance on these forward-looking
statements. All such statements speak only as of the date made, and we
undertake no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
SOURCE: BioAmber Inc.
For further information:
The Trout Group, LLC
New York, NY 10003
Tel: + 1 (646) 378-2947
Fax: +1 (646) 378-2901